Novartis (NYSE: NVS) reported Q2 EPS of $1.34, $0.08 worse than the analyst estimate of $1.42. Revenue for the quarter came in at $14.6 billion versus the consensus estimate of $14.81 billion.

• rowth prospects
  • Zykadia received FDA approval in ALK+ non-small cell lung cancer
  • LCZ696 granted FDA Fast Track designation and agreed to rolling submission in heart failure
  • CART immunotherapy CTL019 granted FDA Breakthrough Therapy status, fifth for Novartis
  • Ophthalmology pipeline strengthened with exclusive ex-US rights to Fovista and positive CHMP opinion for Simbrinza in glaucoma
  • Novartis entered agreement to license Google "smart lens" technology
    
• Strong execution on growth products and emerging markets across divisions in Q2
  • Growth products[3] grew 18% (USD) to USD 4.7 billion, or 32% of Group net sales
  • Strong performance in Emerging Growth Markets[3] (+8% cc), led by Russia and China
    
• Q2 core margin improvement (cc) mainly driven by productivity initiatives
  • 2.1 percentage points (cc) of core margin growth in Pharmaceuticals
  • Group core margin improved (1.1 percentage points cc) mainly due to R&D (0.9 percentage points cc) and M&S (0.5 percentage points cc)

For earnings history and earnings-related data on Novartis (NVS) click here.